Published in Oncol Lett on July 04, 2016
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol (2014) 1.20
Molecular epidemiology of smoking and lung cancer. Oncogene (2002) 1.20
Choline kinase: an important target for cancer. Curr Med Chem (2006) 1.16
Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One (2012) 1.12
A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene (2011) 1.09
Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev (2013) 1.03
Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev (2015) 0.99
Phospholipase D1 and choline kinase-α are interactive targets in breast cancer. Cancer Biol Ther (2014) 0.98
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer (2013) 0.96
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts. PLoS One (2013) 0.90
Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother (2014) 0.87
Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. Mol Cancer Ther (2014) 0.85
A review of 250 ten-year survivors after pneumonectomy for non-small-cell lung cancer. Eur J Cardiothorac Surg (2013) 0.84
Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget (2015) 0.83
[Epidemiological novelties in lung cancer]. Rev Mal Respir (2011) 0.82
Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. Anticancer Res (2013) 0.82
A mechanism for suppression of the CDP-choline pathway during apoptosis. J Lipid Res (2013) 0.81
Choline kinase active site provides features for designing versatile inhibitors. Curr Top Med Chem (2014) 0.81
Detection of lung cancer using multiple genetic markers--a systematic review. Diagn Cytopathol (2013) 0.80
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. Pharmacogenomics (2015) 0.78
Increased BRAF copy number in lung adenocarcinoma. Oncol Lett (2014) 0.78